Email updates

Keep up to date with the latest news and content from Journal of Hematology & Oncology and BioMed Central.

Open Access Highly Accessed Commentary

Lynch syndrome related endometrial cancer: clinical significance beyond the endometrium

Yiying Wang123, Yue Wang123, Jie Li234, Janiel Cragun25, Kenneth Hatch25, Setsuko K Chambers25* and Wenxin Zheng2345*

Author Affiliations

1 Department of Obstetrics and Gynecology, Henan Province People’s Hospital Zhengzhou, Henan, China

2 Department of Obstetrics and Gynecology, University of Arizona, Tucson, AZ, USA

3 Department of Pathology, University of Arizona College of Medicine, Tucson, AZ, USA

4 Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Shandong, China

5 Arizona Cancer Center, University of Arizona, Tucson, AZ, USA

For all author emails, please log on.

Journal of Hematology & Oncology 2013, 6:22  doi:10.1186/1756-8722-6-22

Published: 25 March 2013

Abstract

Lynch syndrome (LS), an autosomal dominant inherited cancer susceptibility syndrome, also known as hereditary non-polyposis colon cancer (HNPCC), is caused by a germline mutation in one of several DNA mismatch repair (MMR) genes. LS is the most common presentation of hereditary colorectal cancer (CRC), accounting for about 2–5% of all CRC cases. More recently, it is found that a similar number of endometrial cancers is also due to one of the MMR gene mutations. There has been significant progress in LS-related CRC in terms of molecular pathogenesis, risks, genetic basis, and cancer prevention. In contrast, the advance about LS-related endometrial cancer (EC) is very much limited. In this commentary, we summarize the main clinicopathologic features of LS-related EC and propose universal screening for LS in individuals with endometrial cancer.